MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 186.16% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD 27.59M.%!(EXTRA int=2)
Fairly Valued
The company’s latest PE is 47.17, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 184.37M shares, increasing 1.19% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 18.10M shares of this stock.